Background. In a recent trial of intermittent preventive treatment in pregnancy (IPTp) in Uganda, dihydroartemisinin-piperaquine (DP) was superior to sulfadoxine-pyrimethamine (SP) in preventing maternal and placental malaria.
Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization in areas of Africa with moderate to high malaria transmission [1] . However, resistance to SP is widespread in eastern and southern Africa [2] , and recent studies have suggested a loss of effectiveness of IPTp with SP [3] [4] [5] [6] . In a recent randomized controlled trial among 300 pregnant women in Tororo, Uganda, an area in which malaria transmission intensity and the prevalence of SP resistance are high [7] , IPTp with the artemisinin-based combination therapy (ACT) dihydroartemisinin-piperaquine (DP) every 4 weeks (DP4w) or every 8 weeks (DP8w) was superior to IPTp with SP every 8 weeks in decreasing parasitemia, symptomatic malaria, and placental malaria. Similarly, in western Kenya, IPTp with DP was associated with decreased parasitemia and symptomatic malaria compared to IPTp with SP [8] .
However, the emergence and spread of Plasmodium falciparum resistance to available antimalarial drugs is a serious threat, and there is concern that IPTp will select for drug resistance.
Mediators of decreased drug sensitivity are characterized for a number of antimalarial drugs. Resistance to antifolates is conferred by polymorphisms in genes encoding 2 enzymes in the folic acid pathway, pfdhps and pfdhfr, the targets of sulfadoxine and pyrimethamine, respectively [9] . A quintuple mutant haplotype, comprised of pfdhfr 51I, 59R, and 108N and pfdhps 437G and 540E, has been associated with SP treatment failure and is highly prevalent in Uganda [10, 11] . Additional mutations at pfdhfr 164 and pfdhps 581 and 613 are associated with high-level SP resistance in South America and Asia, but are uncommon in Africa [9] . Resistance to the aminoquinolines chloroquine and amodiaquine is mediated largely by polymorphisms in putative drug transporters encoded by pfcrt and pfmdr1 [12, 13] . Chloroquine resistance-associated mutations in pfcrt (76T) and pfmdr1 (86Y and 1246Y) have been common in Africa, but with discontinuation of chloroquine and wide use of the ACT artemether-lumefantrine (AL), the prevalence of these mutations has been decreasing in Uganda [10, 14] and other countries [15] [16] [17] . Piperaquine (PQ) is a bisaminoquinoline related to chloroquine and amodiaquine. Use of DP has selected inconsistently for mutations associated with resistance to chloroquine and amodiaquine [14, [18] [19] [20] [21] [22] . Recently, frequent failures have been seen after treatment for uncomplicated malaria with DP in Cambodia [23, 24] . These failures were associated with mutations in the propeller domain of the pfkelch13 gene (PF3D7_1343700) linked to artemisinin resistance [25, 26] , and with 2 polymorphisms (increased copy number of plasmepsin genes [27, 28] and an exonuclease mutation, exo-E415G [28] ) linked to decreased PQ sensitivity. In Uganda, the efficacy of DP for the treatment of malaria remains excellent [29, 30] , pfkelch13 polymorphisms are uncommon and not associated with resistance [31, 32] , and it is unknown if newly identified polymorphisms associated with decreased PQ activity are prevalent.
With few ACT failures in Africa, insights into the emergence and spread of drug resistance can be gained by considering selection by antimalarial drugs of resistance-associated polymorphisms in parasites that emerge after therapy. In Uganda, recent use of DP for both treatment [31] and chemoprevention [19] selected for pfmdr1 mutations associated with decreased sensitivity to these drugs. Interestingly, lumefantrine, a component of the Ugandan first-line ACT AL, exerts the opposite selective pressure. Specifically, parasites that emerged after therapy with AL showed selection of the wild-type polymorphisms pfcrt K76 and pfmdr1 N86 and D1246 [14, 18] . As DP showed clear efficacy advantages, it is under consideration to replace SP for IPTp. To gain insights into effects of different IPT regimens on drug resistance, we compared the prevalences of P. falciparum resistance-associated polymorphisms in samples collected from women enrolled in a trial comparing DP and SP for IPTp.
MATERIALS AND METHODS

Clinical Trial
We assessed polymorphisms of interest in samples collected as part of a double-blind, randomized trial comparing the efficacies of different IPTp regimens in Tororo District, Uganda [7] . In brief, human immunodeficiency virus-uninfected pregnant women between 12 and 20 weeks of gestation were enrolled and randomized to receive (i) SP (500 mg sulfadoxine and 25 mg pyrimethamine) every 8 weeks (20, 28 , and 36 weeks' gestational age), (ii) DP (40 mg dihydroartemisinin and 320 mg PQ) every 8 weeks (20, 28 , and 36 weeks' gestational age [DP8w]), or (iii) DP every 4 weeks (starting at 16 weeks' gestational age [DP4w]). Participants were encouraged to visit the study clinic for all illnesses. Febrile participants with thick blood smears showing parasites were diagnosed with malaria and treated with AL. Capillary or venous blood samples were obtained from participants at enrollment, every 4 weeks during pregnancy, and when malaria was diagnosed. Blood spots were stored on filter paper, and plasma was stored at -80°C for PQ quantitation. DNA was extracted from dried blood spots using Chelex-100 [33] and tested for the presence of Plasmodium DNA by loop-mediated isothermal amplification (LAMP), as previously described [34] . The study was approved by the Makerere University Research and Ethics Committee, the Uganda National Council for Science and Technology, and the University of California, San Francisco Committee for Human Research.
Characterization of Parasite Polymorphisms
Samples were tested for polymorphisms in pfcrt, pfmdr1, pfdhfr, and pfdhps if they were positive for P. falciparum and either the first positive sample (if any) identified for each study participant prior to administration of study drugs (219 samples) or the first positive sample identified following administration of each dose of study drug (122, 37, and 29 samples for the SP, DP8w, and DP4w arms, respectively) ( Figure 1 ). Genotyping was performed using a ligase detection reaction-fluorescent microsphere assay as previously described [35] , with minor modifications including nested polymerase chain reaction (PCR) amplification of templates, as described previously [14, 36] . The pfkelch13 propeller domain was amplified and sequenced as previously described [32] . The exonuclease gene (PF3D7_1362500) was amplified using nested PCR as described in Supplementary Table 1 . PCR products were sequenced in both directions (Eurofins Genomics) using second-round PCR primers. Sequencing results were assembled, visually examined, and aligned with the reference 3d7 sequence using CodonCode version 6.0.2 (CodonCode Corporation). The pfkelch13 and exonuclease gene sequences were submitted to GenBank under accession numbers MF285352-MF285413 and MF285277-MF285277351, respectively.
Plasmepsin-2 (pfpm2) copy number was determined using a TaqMan quantitative PCR assay. Pfpm2 primers and probes were designed with Primer Express 3.0 (Supplementary Table 2 ). The pfpm2 probe was FAM (6-carboxyfluorescein) labeled at the 5ʹ-end and had a minor groove binder quencher at the 3ʹ-end. The β-tubulin primers and probe were as described elsewhere [37] , and were VIC labeled at the 5ʹ-end, with a TAMRA (6-carboxytetramethylrhodamine) quencher at the 3ʹ-end (Thermo Fisher Scientific). Multiplex PCR reactions (20 µL) contained TaqMan Universal PCR Master Mix (Thermo Fisher Scientific), 300 nM of each forward and reverse primer, 100 nM of each probe, and 2 µL of template DNA. Thermocycler conditions were as follows: 2 minutes at 50°C, then 10 minutes at 95°C, followed by 50 cycles of 95°C for 15 seconds and 60°C for 1 minute. All reactions were performed in quadruplicate and contained a single pfpm2 copy control, a multicopy control (generated using pfpm2-containing plasmids with 3-4 copies of the gene and kindly provided by Didier Menard), and a negative control. The pfpm2 and β-tubulin reactions had similar relative amplification efficiencies and were analyzed using the comparative cycle threshold (Ct) method (2 -ΔΔCt ) as applied in the SDS Software package associated with the Applied Biosystems 7500 real-time PCR instrument on which the reactions were run. Pfmdr1 copy number was quantified using TaqMan real-time PCR as previously described [14] . Data were rejected if they did not conform to exponential kinetics. Assays were repeated if (i) the ΔCt standard error was >0.25; (ii) Ct values were >35; or (iii) the relative quantification (RQ) value was <0.70 or >1.3. Data from assays with standard errors >0.25, with Ct values were >35, or RQ values <0.70 were rejected. RQ values were averaged between repeated assays when quality controls were met.
Plasma Piperaquine Quantitation
Venous plasma samples were collected at enrollment, at 20, 28, and 36 weeks' gestation, and at delivery. Capillary samples were obtained at 16, 24, 32, and 40 weeks' gestation, or when malaria was diagnosed. Blood samples were centrifuged within 60 minutes of collection at 2000g for 10 minutes, and plasma was transferred to cryovials and stored at -80°C. Concentrations of PQ were determined using high-performance liquid chromatography-tandem mass spectrometry, as previously described [38] , with the modification that the calibration range was lowered to 0.500-50.0 ng/mL. The lower limit of quantification was 0.500 ng/mL, and the coefficient of variation was <10% for quality control measurements. A correlation equation, InC Capillary = 0.673*lnC venous +1.574, was previously determined for this population [39] , and was used to convert capillary PQ values to venous concentration estimates. Venous and converted capillary PQ concentrations were used for analyses.
Statistical Methods
Data analysis was performed with Stata version 14.0 (StataCorp) and RStudio version 0.99.903 (RStudio, Inc) software. Outcomes of interest were the prevalence of mutant alleles (including mixed infections for transporter loci and excluding mixed infections for folate loci) for each locus of interest, the prevalence of pfmdr1 and pfcrt haplotypes, and the prevalence of the quintuple folate mutant haplotype (pfdhfr 51I, 59R, and 108N and pfdhps 437G and 540E). For pfmdr1 and pfcrt haplotypes, mixed-genotype samples were excluded. The quintuple mutant haplotype was considered present if a sample had only mutant genotypes at all 5 loci, and absent if there were wild-type or mixed genotypes at any of the loci. Samples with missing data were excluded. Exposure variables of interest were the IPTp arm to which the patient was randomized, the duration of time since IPTp dosing, and the plasma PQ concentration. Associations between outcomes and categorical exposure variables were measured in Stata using log-binomial regression with generalized estimating equations to account for repeated measures in the same patient. Associations between prevalences of mutant alleles and PQ concentrations were measured using generalized linear models in the R package "ggplot2, " implementing binomial variance and logit link functions. A P value <.05 was considered significant.
RESULTS
Impact of DP on Transporter Polymorphisms
We compared the prevalence of mutant alleles (mixed genotype and pure mutant infections) at pfmdr1 N86Y, pfmdr1 Y184F, pfmdr1 D1246Y, and pfcrt K76T in P. falciparum-infected samples before and after the initiation of study drugs and between patients assigned to receive DP or SP. Treatment with DP was associated with increased prevalences of mutant alleles at pfmdr1 86Y, pfmdr1 184F, and pfcrt 76T compared to no treatment (samples collected before treatment was initiated; 64.6% vs 21.6%, P < .001; 93.9% vs 59.2%, P < .001; and 87.7% vs 74.1%, P = .004, respectively) or treatment with SP (64.6% vs 27.4%, P < .001; 93.9% vs 59.2%, P < .001; and 87.7% vs 75.4%, P = .03, respectively; Table 1 and Figure 2 ). Treatment with DP was associated with decreased prevalence for mutant pfmdr1 1246Y compared to no treatment (6.3% vs 26.6%, P = .02) or treatment with SP (6.3% vs 22.4%, P = .03). We found no differences in the prevalence of transporter polymorphisms between the samples collected before treatment and from individuals treated with SP. Considering impact of DP on haplotypes, we found that receipt of DP was selected for the pfmdr1 N86-184F, pfmdr1 86Y-D1246, pfmdr1 N86-184F-1246D, and pfcrt 76T-mdr1 N86-184F-1246D haplotypes (Supplementary Tables 3-6 ).
We considered recent use of AL as a potential confounder. The proportion of samples collected within 60 days of prior AL treatment did not differ statistically between the treatment arms (11% in the SP arm and 5% in the DP arms, P = .18), and, when analyzed as a covariate, was not associated with differences for any of the considered loci.
Considering DP dosing frequency, all 4 transporter loci demonstrated at least a modest dose effect ( Figure 3A) , with more frequent dosing associated with increased differences in allele prevalences between treatment arms, although the difference between the DP8w and DP4w arms was significant only for pfmdr1 86 (48.7% vs 85.7%, P = .003; Table 2 ). Considering time since last DP dosing, recent (within 4-28 days) DP dosing was associated with an increase in the prevalence of pfmdr1 86Y mutant infections compared with dosing 29-56 days before sample collection (73.9% vs 42.1%, P = .04; Table 2 and Figure 3B ).
Association Between Piperaquine Plasma Concentrations and Loci
Associated With Drug Resistance
A PQ concentration was available for 56 of the 66 (85%) genotyped samples with prior exposure to DP. We used generalized linear models to determine the relationship between the prevalence of infections with mutant transporter genotypes and the plasma concentration of PQ. Increasing PQ concentration was associated with increasing prevalence of the mutant pfmdr1 86Y allele, consistent with the selection observed in the DP treatment arms (Figure 4 ). In samples with PQ concentrations >2.70 ng/ mL, the prevalence of mutant infections was 94.1% (16/17) ; in contrast, in samples with PQ concentrations ≤2.70 ng/mL, the prevalence of mutant infections was 44.4% (20/45) (prevalence ratio, 2.16 [95% confidence interval, 1.56-2.99], P < .001). Only parasites with the pfmdr1 86Y mutant genotype were seen in samples with PQ levels >2.75 ng/mL.
Markers of Artemisinin and Piperaquine Resistance
Sequencing of 61 randomly selected samples detected pfkelch mutations in 2 of 19 samples collected from patients receiving DP (A569T and G638R), 1 of 22 samples from patients receiving SP (N594K), and 0 of 20 samples collected before the initiation of chemoprevention. None of these mutations have been reported to be associated with decreased sensitivity to artemisinins [26, 40] , and the prevalences of pfkelch13 mutations did not differ significantly between treatment groups. We detected no clear evidence of increased pfmdr1 copy number, although average RQ values between 1.3 and 1.5 were detected for 7 of 46 samples. The prevalence of these modest increases did not vary between treatment arms.
Considering recently identified polymorphisms associated with decreased PQ sensitivity, we measured pfpm2 copy number variation and sequenced a 395-bp amplicon surrounding the exo-E415G locus. We detected modest increases in pfpm2 copy number in 1 of 18 samples from patients receiving DP (RQ = 1.3), 1 of 21 samples from patients receiving SP (RQ = 1.3), and 1 of 27 samples collected before the initiation of chemoprevention (RQ = 2.1). We did not detect the exo-E415G mutation, but we detected other nonsynonymous exo mutations 
Impact of SP on Folate Polymorphisms
We compared the prevalences of mutant alleles at pfdhfr N51I, C59R, S108N/T, and I164L and pfdhps A437G, K540E, A581G, and A613S before and after the initiation of study drugs, and between patients assigned to receive DP or SP. Although the population had high prevalences of mutant alleles at pfdhfr 51, 59, and 108 and pfdhps 437 and 540 (>85% for all loci in samples collected before the initiation of study drugs), treatment with SP was associated with increased prevalences for mutant alleles at pfdhfr 59, pfdhps 540, and the quintuple mutant haplotype compared to samples collected prior to the administration of study drugs (96.7% vs 87.9%, P = .001; 91.2% vs 85.1%, P = .11; and 90.8% vs 77.8%, P = .002, respectively) or samples collected from the DP arm (96.7% vs 76.9%, P = .002; 91.2% vs 71.4%, P = .009; and 90.8% vs 60.0%, P = .001, respectively) ( Table 3 and Figure 2 ). We found no differences in allele prevalences between samples from patients dosed with SP 29-76 or 2-28 days prior to sample collection.
DISCUSSION
We surveyed established and recently described P. falciparum drug resistance markers in samples from subjects randomized to receive DP or SP as IPTp. DP selected for mutant alleles at pfmdr1 86, pfmdr1 184, and pfcrt 76, and against mutant alleles at pfmdr1 1246, and this selection increased with increasing PQ exposure. Recently described markers of artemisinin resistance and PQ resistance were uncommon. SP selected for mutant alleles at pfdhfr 59 and pfdhps 540, and for the quintuple pfdhfr/pfdhps mutant haplotype, all of which confer resistance to antifolate drugs. Our findings indicate that IPTp with DP or SP selects parasite genotypes previously associated with decreased sensitivity to these regimens, but polymorphisms associated with clinically relevant DP resistance in Southeast Asia appear not to have emerged in Uganda. The transporter polymorphisms pfmdr1 N86Y, pfmdr1 D1246Y, and pfcrt K76T modulate parasite sensitivity to numerous antimalarials. Mutant pfmdr1 86Y, pfmdr1 1246Y, and pfcrt 76T are selected by prior use of the aminoquinolines chloroquine and amodiaquine and associated with reduced sensitivity to these drugs [18, 30, [41] [42] [43] [44] . In contrast, wild-type sequences at these same alleles are selected by prior use of AL and associated with reduced sensitivity to lumefantrine [14, 30, [45] [46] [47] . Another allele, pfmdr1 Y184F, is also highly polymorphic, but its relationship to antimalarial sensitivity is not straightforward [13] and may be haplotype dependent [48] .
Piperaquine is similar in structure to chloroquine and amodiaquine, but perhaps due to its larger size, its selective pressure on transporter mutations and the impacts of these mutations on drug sensitivity differ [19] . Our new results, considering Prevalence (%) Figure 2 . Prevalence of wild-type, mixed, or mutant alleles at Plasmodium falciparum loci of interest in parasitemic samples collected from patients before intermittent preventive treatment in pregnancy (IPTp) treatment was initiated (None), in patients receiving sulfadoxine-pyrimethamine (SP) as IPTp, and in patients receiving dihydroartemisinin-piperaquine (DP) as IPTp.
impacts of DP when used for IPTp, are generally consistent with those seen in Uganda for DP used for treatment [14] or prevention [18, 19] of malaria in children. Most clearly, prior use of DP selects for parasites with increased prevalence of the pfmdr1 86Y mutation. This selection is the same as that of other aminoquinolines, and opposite that of lumefantrine. Results have been more complex for other alleles. Notably, for pfmdr1 D1246Y, our new results show selection by DP of wild-type D1246 parasites, opposite the selection seen with amodiaquine-containing regimens [43] and also opposite that with DP in some [14, 18] , but not other [19] , studies. For pfcrt, DP selected for the 76T mutation associated with resistance to other aminoquinolines, the same selection seen in one other recent study [19] but not others [14, 18] . Taken together, our results suggest that DP selects in Uganda for the pfmdr1 86Y mutation and other polymorphisms associated with resistance to aminoquinolines, but results for alleles other than 86Y have been inconsistent, and specific selection appears to depend on background parasite sequences that vary geographically. Our study benefited from the availability of plasma PQ levels at the time of presentation with parasitemia or symptomatic malaria. The selective effects of DP were clearly dose dependent, with greater selection of the pfmdr1 86Y mutation and other alleles with increased exposure. However, selection for mutant pfmdr1 86Y occurred at low concentrations, and only parasites with the mutant 86Y allele were detected at PQ concentrations >2.75 ng/mL. In a recent study in Uganda, mean PQ levels 21 days after treatment were 11.8 ng/mL in pregnant women and 14.5 ng/mL in nonpregnant women [39] . Recent surveys have shown that the prevalence of parasites with the wildtype pfmdr1 N86 allele has increased to >90% in multiple sites across Uganda [10] . Taken together, our results suggest that, in Abbreviations: CI, confidence interval; DP, dihydroartemisinin-piperaquine; IPTp, intermittent preventive treatment in pregnancy; NA, not applicable; SP, sulfadoxine-pyrimethamine.
Uganda, with nearly all parasites now harboring the pfmdr1 N86 genotype, monthly DP will be highly effective, with minimal incidence of breakthrough parasitemia, but that continued drug pressure might select for pfmdr1 86Y mutant parasites more likely to cause breakthroughs. It should be noted that although more frequent DP dosing was associated with stronger selection of resistance mutations, it was also more protective against parasitemia during pregnancy. Only 26 of 496 (5.2%) samples collected from the DP4w arm during our trial demonstrated parasitemia with a highly sensitive LAMP assay, compared to 74 of 445 (16.6%) samples from the DP8w arm. Determining the ideal dosing regimen to minimize exposure of parasites to PQ concentrations that are high enough to select for resistance but too low to eliminate parasitemia will be of importance to ensure the continued efficacy of DP as IPTp.
Mutations at 5 loci in the folate enzyme genes associated with resistance to SP have long been highly prevalent in Uganda [10, 49] . We detected significant selection by SP of the common mutations most clearly associated with SP resistance, pfdhfr 59R and pfdhps 540E [49] . These results reinforce concerns about the continued protective efficacy of SP as IPTp and the consequences of its continued use. Reassuringly, additional mutations associated with higher-level resistance to SP, notably pfdhfr 164L and pfdhps 581G, which have shown modest increases in prevalence in some regions of Uganda [10] , were not selected by SP when used for IPTp.
Our results have important implications for the choice of drug for IPTp. We have previously demonstrated the superiority of DP over SP for young children [50] , schoolchildren [19] , and pregnant women [7] . Our current results show that, when used as IPTp, both DP and SP select for P. falciparum mutations previously associated with decreased sensitivity to the drugs. In the case of DP, low nanomolar PQ levels that are maintained for weeks after standard dosing were protective against drug-sensitive parasites currently circulating in Uganda, but associated with selection of parasites harboring mutations previously associated with decreased susceptibility. Importantly, for the most part, the selective pressure of DP on transporter polymorphisms is opposite that of AL, the national malaria treatment regimen in Uganda. As a result, AL selects for parasites that are highly sensitive to DP. Thus, a rational strategy to effectively treat and control malaria while limiting resistance selection may be to continue to use AL to treat malaria while instituting DP for chemoprevention in high-risk groups.
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